Source-grounded facts extracted from Cryoport, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cryoport, Inc. reported first quarter (Q1) of 2026 results: revenue $47.8 million. Guidance raised.
“99.1) --- EX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2026 Financial Results ● First quarter revenue grew 16% year-over-year to $47.8 million ● Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs ● Life Sciences Services”
Cryoport, Inc. completed a disposition involving designated affiliates of DHL Supply Chain International Holding B.V. for cash payments of approximately $200 million to Cryoport (closed 2025-06-11).
“specialty courier business, CRYOPDP, to DHL Group ( “ DHL ” ), one of the world ’ s leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport. Concurrently, Cryoport and DHL have established a strategic partnership aimed at enhancing their respective supply chain service offerings for the global life”
Cryoport, Inc. reported the first quarter ended March 31, 2024 results: revenue $54.6 million, net income $0.43 per share, EPS $0.43 per share. Guidance reaffirmed.
“filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2413756d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials”
Cryoport, Inc. reported the fiscal year ended December 31, 2023 results: revenue $233.3 million.
“Today we reported full year results including total revenue of $233.3 million for the fiscal year ended December 31, 2023.”
Cryoport, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $57.3 million.
“Total revenue for Q4 2023 was $57.3 million compared to $60.4 million for Q4 2022”
Edward Zecchini changed role as Senior Vice President – Chief Digital & Technology Officer at Cryoport, Inc..
“On February 10, 2024, Edward Zecchini accepted the offer to join Cryoport, Inc. (the “Company”) as Senior Vice President – Chief Digital & Technology Officer and submitted his resignation from the Board of Directors of the Company both effective February 19, 2024.”
Cryoport, Inc.: Amended and restated bylaws to update director nomination procedures, proxy card color requirements, and compliance with Rule 14a-19 under the Exchange Act (effective 2023-11-09).
“On November 9, 2023, as part of its periodic review of corporate governance matters and in connection with the universal proxy rules adopted by the Securities and Exchange Commission, the Board of Directors (the "Board") of Cryoport, Inc. (the "Company") adopted an amendment and restatement of the Company's Amended and Restated Bylaws (as so amended and restated, the "Amended and Restated Bylaws"), effective as h, in order to, among other things: · update the procedural and disclosure requirements for the nomination for directors, including, among other things, requiring that any stockholder seeking to nominate director(s) at a stockholder's meeting provide the Company with certain representations, information and evidence regarding compliance with Rule 14a-19 under the Securities Exchange Act, as amended (the "Exchange Act"); · implement a requirement that any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, wi”
Cryoport, Inc. reported the third quarter ended September 30, 2023 results: revenue $56.2 million. Guidance reaffirmed.
“new therapy approvals and an additional seven label/ geographic expansions or moves to earlier lines of treatment approved. Financial Highlights Total revenue for Q3 2023 was $56.2 million compared to $60.5 million for Q3 2022, a year-over-year decrease of 7% or $4.3 million. • Biopharma/Pharma revenue was $47.0 million, down 3% or $1.6 million for Q3 2023 compared”
Cryoport, Inc. reported the second quarter ended June 30, 2023 results: revenue $57.0 million.
“--- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2323346d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2023 Financial Results § Second quarter revenue of $57 million, in line with previously announced preliminary results § Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of”
Cryoport, Inc. reported full year 2023 results: revenue $233 to $243 million. Guidance lowered.
“Based on current information, the Company is revising its full year financial outlook, with revenue now expected to be in the range of $233 to $243 million for 2023.”
Cryoport, Inc. reported the second quarter ended June 30, 2023 results: revenue $56.5 to $57.5 million.
“Second quarter 2023 total revenue is expected to be in the range of $56.5 to $57.5 million”
Cryoport, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement at the 2023-05-12 meeting.
“Proposal No. 3: Advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. This proposal was approved as set forth below: Votes For Votes Against Abstentions Broker Non-Votes 42,966,805 1,608,485 27,465 2,774,040”
Cryoport, Inc. shareholders approved Ratification of the appointment of Deloitte and Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2023 at the 2023-05-12 meeting.
“Proposal No. 2: Ratification of the appointment of Deloitte and Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2023. This proposal was approved as set forth below: Votes For Votes Against Abstentions Broker Non-Votes 47,362,220 10,936 3,639 —”
Cryoport, Inc. shareholders approved Election of Directors at the 2023-05-12 meeting.
“The individuals listed below were elected to serve as directors of the Company until the Company’s 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified or their earlier death, resignation, or removal: Director Nominee Votes For Votes Withheld Broker Non-Votes Linda Baddour 43,594,307 1,008,448 2,774,040 Richard Berman 28,709,314 15,893,441 2,774,040 Daniel M. Hancock 43,599,728 1,003,027 2,774,040 Robert Hariri, M.D., Ph.D. 26,694,207 17,908,548 2,774,040 Ram M. Jagannath 43,444,923 1,157,832 2,774,040 Ramkumar Mandalam, Ph.D. 23,771,230 20,831,525 2,774,040 Jerrell W. Shelton 43,151,882 1,450,873 2,774,040 Edward J. Zecchini 43,600,450 1,002,305 2,774,040”
Cryoport, Inc. reported the first quarter ended March 31, 2023 results: revenue $62.8 million.
“We are pleased to report that we delivered record revenue of $62.8 million for the first quarter”
Cryoport, Inc. dismissed Ernst & Young LLP as its auditor.
“The Company notified EY on March 9, 2023 that it would be dismissed as the Company's independent registered public accounting firm, effective as of March 9, 2023”
Cryoport, Inc. engaged Deloitte & Touche LLP as its auditor.
“Change in Registrant’s Certifying Accountant Appointment of New Independent Registered Public Accounting Firm On March 9, 2023, Cryoport, Inc. (the “Company”), at the direction of the Audit Committee of the Board of Directors of the Company (the “Audit Committee”), approved the appointment of Deloitte & Touche LLP (“Deloitte”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2023 and the dismissal of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, in each case, effective as of March 9, 2023. The engagement of Deloitte is subject to completion of Deloitte’s standard client acceptance procedures and”
Cryoport, Inc. reported the fiscal year ended December 31, 2022 results: revenue $237.3 million. Guidance initiated.
“Cryoport delivered a solid finish to 2022 with total revenue of $237.3 million”
Cryoport, Inc. reported the three months ended December 31, 2022 results: revenue $60.4 million. Guidance initiated.
“Total revenue for the fourth quarter of 2022 was $60.4 million compared to $56.4 million for the fourth quarter of 2021, a year-over-year increase of 7%”
Cryoport, Inc. reported the third quarter ended September 30, 2022 results: revenue $60.5 million. Guidance lowered.
“Cryoport Reports Results for the Third Quarter 2022 § Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems’ revenue up 25% year-over-year”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.